An analysis of phase 2 and phase 3 data on a travoprost implant (iDose TR; Glaukos) where the implant was compared to timolol found neither the slow or fast-eluting models result in a clinically significant loss in endothelial cell density (ECD) in the 12-month period following administration or readministration, according to a poster presented by Mark J. Gallardo, MD, during the 2023 annual meeting of the American Academy of Ophthalmology.

Endothelial cell density was measured at baseline, month 3, and month 12 in 205 implant subjects and 102 timolol subjects, and in 33 subjects who underwent readministration of an implant. No subject experienced an adverse event of corneal endothelial cell loss through month 12.